New combo vaccine aims to shield seniors from two dangerous respiratory viruses

NCT ID NCT05903183

Completed ⭐️ VACCINE ⭐️ Sponsor: Icosavax, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new vaccine called IVX-A12 that targets two respiratory viruses: RSV and hMPV. It involved 264 healthy adults aged 60 to 85. The goal was to see if the vaccine is safe and boosts the immune system to fight these viruses.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

respiratory syncytial virus infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Show contact details

Locations

AMR Lexington

Lexington, Kentucky, 40509, United States
AMR Phoenix

Tempe, Arizona, 85281, United States
ASR, LLC

Nampa, Idaho, 83587, United States
Cenexel RCA

Hollywood, Florida, 33024, United States
Clinical Research Atlanta

Stockbridge, Georgia, 30281, United States
Johnson City Clin-Trials (JCCT)

Lenexa, Kansas, 66219, United States
PanAmerican Clinical Research

Brownsville, Texas, 78520, United States
Rochester Clinical Research, Inc

Rochester, New York, 14609, United States
Velocity Clinical Research

Omaha, Nebraska, 68134, United States
Velocity Clinical Research-Boise

Meridian, Idaho, 83642, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.